

Mario U Mondelli, MD PhD FRCP

Professor of Infectious Diseases

University of Pavia and

Fondazione IRCCS Policlinico San Matteo

CURRICULUM VITÆ

1. Personal Details:

Date of birth: May 29, 1954
Place of birth: Milan, Italy
Nationality: Italian
Marital Status: Married, three children
Fiscal Code: MND MMB 54E29 F205L



Present appointment: Professor of Infectious Diseases, Department of Internal Medicine, University of Pavia, and Director, Research Laboratories, Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Consultant Physician, Fondazione IRCCS Policlinico San Matteo.

Address: (work) Dipartimento di Malattie Infettive, Fondazione IRCCS Policlinico San Matteo, via Taramelli 5, 27100, Pavia, Italy
Tel: +39-0382-502 636(direct)
Mobile: +39-335-711 5496
Fax: +39-0382-526 450
e-mail: mario.mondelli@unipv.it

(home) via Vitali 1, 20122, Milano, Italy
Tel: +39-02-796 078

2. Personal statement:

I worked for several years in academic environments gaining substantial international experience in clinical and translational research. My research profile is well known internationally and I am considered a KOL in the field of Hepatology in general and viral hepatitis in particular. I am seeking new challenges in a competitive and stimulating environment and would be interested to consider using my broad experience for new professional challenges. I am well-mannered, have charismatic leadership and enthusiastic approach to translational and clinical research. I believe that my background could provide a substantial asset to any academic or non-academic environment.

3. Education/Qualifications:

University: Medicine and Surgery – University of Milan, Italy (1972-1978)
Graduated as Medical Doctor *summa cum laude*.

Registered Specialist (I): Gastroenterology (1982)
Allergy and Clinical Immunology (1991)

Postgraduate
Qualifications:

i) Board Certificate for Specialist in Gastroenterology (1978-1982)
This four-year period involved 4 to 6 months rotations through all subspecialties of Gastroenterology, yearly assessments and a final examination (*summa cum laude*).

ii) Board Certificate for Specialist in Allergy and Clinical Immunology (1988-1991). Training focused specifically on allergic and autoimmune diseases, yearly assessments and a final examination.

Postgraduate
Research Training:

Fellowships from Rusconi Foundation (Italy), The National Research Council (Italy), and The Cystic Fibrosis Research Trust (UK) for research projects in viral hepatitis and liver disease in children with cystic fibrosis all held at the Liver Unit, King's College School of Medicine & Dentistry, London between:
May 1980 – September 1984.

John E. Fogarty International Research Fellowship from the US Public Health Service and Visiting Investigator, Department of Molecular and Experimental Medicine, Research Institute of Scripps Clinic, Scripps Clinic and Research Foundation, La Jolla, California, USA.

i) January 1986 – September 1987

ii) June 1988 – December 1988

Scientific degree:

PhD (1988), University of Pavia, Italy.
Thesis: "Immune responses to hepatitis B virus".

4. Professional History:

2017 – Current	Head, Division of Infectious Diseases and Immunology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
2016 - Current	Vice-Chairman, Scientific Affairs, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
2008 – Current	Director, Post-Graduate School of Infectious and Tropical Diseases, University of Pavia, Italy.
2001 – Current	Professor of Infectious Diseases, Department of Internal Medicine and Therapeutics, University of Pavia, and Consultant, Department of Medical Science and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Italy

- 1997 – 2016 Director, Research Laboratories, Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- 1992 – 2001 Associate Professor of Infectious Diseases, University of Pavia, Italy. Honorary Senior Registrar (1992-1995) and Honorary Consultant (1996-2001), Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- 1989 – 1991 Senior Research Fellow, Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- 1986 - 1988 Research Fellow, Department of Molecular and Experimental Medicine, Research Institute of Scripps Clinic, Scripps Clinic and Research Foundation, La Jolla, California, USA.
- 1985 Clinical Fellow, Division of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (*equivalent to Registrar grade*)
- 1982 - 1984 Cystic Fibrosis Research Trust Fellow & Honorary Registrar, Liver Unit, King's College School of Medicine & Dentistry, London
- 1980 - 1982 Research Fellow, Liver Unit, King's College School of Medicine & Dentistry, London
- 1978 - 1979 House Officer, Maggiore Hospital, University of Milan.

5. Other Appointments and Affiliations:

- Society Memberships: Società Italiana di Malattie Infettive e Tropicali.
 Associazione Italiana per lo Studio del Fegato.
 European Association for the Study of the Liver (EASL)
(Member of EASL Scientific Committee, 1994-1999, Secretary General 1995-1997)
 American Association for the Study of Liver Diseases.
 European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
(Member European Committee on Infection Control EUCIC 2016-current; Professional Affairs Committee 2009-2014;

President ESCMID Study Group on Viral Hepatitis (ESGVH) 2017-current)

International Association for the Study of the Liver (IASL)
(*President 2013-2015*)

Editorial Function:

Journal of Hepatology (1991–1999)
Digestive and Liver Disease (2001–2004)
Journal of Hepatology, *Associate Editor* (1999–2004)
Journal of Hepatology, *Co-Editor* (2005–2009)
European Journal of Clinical Investigation, *Associate Editor*,
(2010-2014)
Liver International, *Editor-in-Chief* (2014-)
PLoS ONE, *Academic Editor* (2014-)

Honours:

1995-97: Scientific Secretary, European Association for the Study of the Liver (EASL).
1997-99: Administrative Secretary, EASL.
1995-00: Council Member, United European Gastroenterology Federation (UEGF).
1999: Vice-Chairman, UEGF.
2000: Chairman, UEGF.
1996-2000: Councillor, International Association for the Study of the Liver (IASL).
2009-2015: President, European Union of Medical Specialists, Section of Infectious Diseases (UEMS-ID).
2009. Fellow of the Royal College of Physicians (FRCP).
2011-14. Member, EASL Ethics Committee.
2013-15: President, International Association for the Study of the Liver (IASL).
2017-current: President, ESCMID (European Society of Clinical Microbiology and Infectious Diseases) Study Group of Viral Hepatitis.
2017-current. ESCMID Fellow.
2018: Recipient of the European Association for the Study of the Liver Recognition Award

Reviewer for the following journals:

Gastroenterology, Hepatology, Journal of Hepatology, Journal of Infectious Diseases, Liver International, Clinical Infectious Diseases, Digestive and Liver Disease, Digestive Diseases and Sciences, Infection, Hybridoma, European Journal of Clinical Investigation, Journal of Clinical Microbiology, Haematologica, Journal of Viral Hepatitis, Journal of Virology, Journal of Medical Virology, Digestion, Journal of Immunology, PLoS Pathogens, PLoS One, Science Translational Medicine, JAIDS, European Journal of Immunology, Nature Communications, Science.

Reviewer for the
following granting
bodies or institutions:

European Union, Biomed 3, The Italian Ministry of Health, The Italian Ministry of Education, University and Research, The Israel Science Foundation, The Health Research Board of Ireland, The Wellcome Trust, U.K., Institut Pasteur, France, Hadassah University, Jerusalem, Israel, the Singapore Institute for Clinical Sciences.

6. Selected invited lectures

- 1) **Mondelli MU**. Cell-mediated immunity to HBV proteins. The Liver Unit, King's College Hospital, London, 1988.
- 2) **Mondelli MU**. Recent approaches to the analysis of the role of T cells in HBV infection. 7th International Congress of Immunology, Berlin, 1989.
- 3) **Mondelli MU**. Experimental models for the pathogenesis of HBV in man. President's premeeting, XLIV Meeting of the German Society of Gastroenterology, Mainz, 1989.
- 4) **Mondelli MU**. The cellular basis of the immune response to hepatitis B virus in man. Division of Molecular Virology, Baylor College of Medicine, Houston, 1990.
- 5) **Mondelli MU**. Significance and specificity of the immune response to HCV. Liver Disease in the 1990's, 25th anniversary scientific meeting. Institute of Liver Studies, King's College School of Medicine and Dentistry, London, 1991.
- 6) **Mondelli MU**. B-cell epitopes on hepatitis C virus. Abteilung Gastroenterologie und Hepatologie, Medizinische Hochschule, Hannover, 1992.
- 7) **Mondelli MU**. B-cell response to hepatitis C virus. Falk Symposium No. 70: Immunology and Liver, Basel Liver Week 1992, 1992.
- 8) **Mondelli MU**. Immune responses in hepatitis C. Annual Meeting of the Irish Society for Immunology. Dublin 1992.
- 9) **Mondelli MU**. *Selected posters discussant*. XXVIII Meeting of the European Association for the Study of the Liver, Paris, 1993.
- 10) **Mondelli MU**. Production and characterization of human monoclonal antibodies to hepatitis C virus. Meeting on "Biotechnology - a potent tool for basic research". Cooperation of Coimbra Group Universities, Bologna, 1995.
- 11) **Mondelli MU**. Significance and specificity of the antibody response to hepatitis C virus. Liver Unit, Hadassah University Hospital, Jerusalem 1996.

- 12) **Mondelli MU**, Perrillo RP. Breakfast session: "The clinical significance of virus-specific immune response". IX Triennial Symposium on Viral Hepatitis and Liver Disease, Roma, 1996.
- 13) **Mondelli MU**. Role of the immune system in liver damage. 2nd EASL Postgraduate Course on "Viral and immune liver damage", Szczecin, Poland, 1996.
- 14) **Mondelli MU**. HCV humoral immune response. Workshop: "HCV and host response before and after liver transplantation", Göttingen, 1996.
- 15) **Mondelli MU**. Viral heterogeneity and outcome of hepatitis C. Eli Lilly and Co., Indianapolis, IN, USA, 1997.
- 16) **Mondelli MU**. Is Hepatitis G virus a problem in paediatric hepatology? International Meeting on Paediatric Hepatology. Chronic Viral Hepatitis in Childhood: Natural History and Interferon Treatment. Sorrento, Italy, 1997.
- 17) **Mondelli MU**. Influence of viral heterogeneity on the outcome of hepatitis C. XIV Meeting of the Turkish Society of Gastroenterology, Mersin, Turkey, 1997.
- 18) **Mondelli MU**. Invited co-chairman/organiser and speaker at the Symposium "Hepatitis 1997", 6th United European Gastroenterology Week, Birmingham, 1997.
- 19) **Mondelli MU**. Immune response to HCV: Hepatitis C: Leading-Edge Scientific and Clinical Advances, Montecarlo, Monaco, 1998.
- 20) **Mondelli MU**. Immunopathogenesis of Viral Hepatitis: EASL Postgraduate Course & First Hepatology Day, Istanbul, 1998.
- 21) **Mondelli MU**. Immune responses to HCV and viral heterogeneity. Immunology in liver disease: basis for present and future therapy. 11th World Congress of Gastroenterology. Vienna, 1998.
- 22) **Mondelli MU**. Natural history of viral hepatitis. 1st Mediterranean Summer School, Samos, Greece, 21-24, 1998.
- 23) **MU Mondelli**. Clinical implications of viral genotypes. EASL International Consensus Conference on Hepatitis C. Paris, France, 1999.
- 24) **Mondelli MU**. Does the immune response play a role in the selection of HCV variants? IX International Symposium on viral hepatitis. Madrid, 2000.
- 25) **Mondelli MU**. HCV Immunology. "Optimizing the treatment of HCV". Schering-Plough Symposium, Madrid, 2000.
- 26) **Mondelli MU**. Significance of hepatitis C virus genotypes and variants. 8th United European Gastroenterology Week, Brussels, 2000.
- 27) **MU Mondelli**. Immune response and HCV variability. Invited seminar. Istituto di Ricerche in Biomedicina, Bellinzona, Switzerland, 2002.

- 28) **MU Mondelli.** HCV variability and antiviral immune response. 2002 International Symposium on Liver Diseases Progress, Chongqing, China, 2002.
- 29) **MU Mondelli.** Mechanism of the liver disease induced by HCV. Course "Hepatitis C virus infection", Valencia, Spain, 2002.
- 30) **MU Mondelli.** How the host fights HCV: the immunologist's point of view. 10th United European Gastroenterology Week, Geneva, Switzerland, 2002.
- 31) **MU Mondelli.** Variability or conservation of the hepatitis C virus hypervariable region 1? X International Symposium on Viral Hepatitis, Madrid, 2003.
- 32) **MU Mondelli.** Regulatory cell subsets involved in immunotolerance and immunosuppression. III International Symposium on Immunology and the Liver: Immunotherapy. Madrid, 2004.
- 33) **MU Mondelli.** Effects of immunosuppressive drugs on HCV and HBV. 10th International Meeting of French Study Group on Molecular Hepatology (GEMHEP), 2005.
- 34) **MU Mondelli.** Antiviral + immunomodulatory agents. EASL Monothematic Conference: from Viral Pathobiology to the Treatment of Hepatitis B Virus Infection. Istanbul, 2005.
- 35) **MU Mondelli.** Predictors of disease severity: HCV. European Association for the Study of the Liver School of Hepatology, Milan, 2005.
- 36) **MU Mondelli.** Linking viral infections to autoimmunity: B-cell activation in chronic hepatitis C. IV International Meeting on Immunology and the Liver: Inflammation, Repair and Therapies, Madrid, Spain, 2006.
- 37) **MU Mondelli.** B cells. EASL Monothematic Conference: Clinical Immunology in Viral Hepatitis, London, 2006.
- 38) **MU Mondelli.** Immune response to HCV. IX International Symposium on Viral Hepatitis, Barcelona 20-21 June 2008.
- 39) **MU Mondelli.** Extrahepatic manifestations of chronic HCV infection. Lecture delivered at Cairo University, Egypt, October 2009.
- 40) **MU Mondelli.** Innate and adaptive immune responses in viral hepatitis: phenotypic changes and altered function of NK and B cells. Meeting with Johns Hopkins and San Matteo, Baltimore, USA, July 8-9, 2010.
- 41) **MU Mondelli.** NK cells in hepatic infections. Workshop SIICA: Innate immunity in the pathogenesis of immune-mediated human diseases. Milan, Italy, November 3-4, 2010.
- 42) **MU Mondelli.** Immunopathogenesis of hepatitis C virus infection. Deutsche Gesellschaft für Immunologie. Riccione, Italy, October 1, 2011.
- 43) **MU Mondelli.** The Role of B Cells in Liver Disease and Autoimmunity. Hepatology 2011 and Beyond, Hannover, 12/2/2011.

- 44) **MU Mondelli.** Natural history of hepatitis B. IASL Post-graduate course of Hepatology. Asunción, Paraguay, Oct. 2011.
- 45) **MU Mondelli.** Therapy of chronic hepatitis B. IASL Post-graduate course of Hepatology. Asunción, Paraguay, Oct. 2011.
- 46) **MU Mondelli.** Innate immunity and hepatitis C virus. Jikei University, Tokyo, Japan, 7/9/2012.
- 47) **MU Mondelli.** Natural Killer Cells in Chronic Hepatitis B and Chronic Hepatitis C Virus Infections. AISF-SIICA Joint meeting: Liver Immunology. 5-7/12/2012.
- 48) **MU Mondelli.** Innate immune responses to HCV. 15th International Congress of Immunology, Milan, August 2013.
- 49) **MU Mondelli.** Hepatorenal Syndrome. Middle East School of Hepatology, Dubai, November 2013.
- 50) **MU Mondelli.** Bacterial infections in cirrhosis. Middle East School of Hepatology, Dubai, November 2013.
- 51) **MU Mondelli.** The HCV Epidemics and its Cure(s): Placing the State of the Science into Much Needed Context and perspective. 4th International Conference on Viral Hepatitis, New York City, USA, March 2014.
- 52) **MU Mondelli.** Invited discussant, Clinical Grand Round. ECCMID, Barcelona, May 2014.
- 53) **MU Mondelli.** Infectious Diseases throughout Europe: a family tree in 2014. 3rd ESCMID Workshop on Professional Affairs in Clinical Microbiology and Infectious Diseases: The Future of Clinical Microbiology and Infectious Diseases in Europe, Ljubljana, June 2014.
- 54) **MU Mondelli.** Hepatitis C therapy revolution. Who should be in charge: ID specialists, hepatologists or GPs? 3rd ESCMID Workshop on Professional Affairs in Clinical Microbiology and Infectious Diseases: The Future of Clinical Microbiology and Infectious Diseases in Europe, Ljubljana, June 2014.
- 55) **MU Mondelli.** Drug-Induced Liver Injury. Joint Postgraduate Course International Association for the Study of the Liver/Chinese Medical Association, Beijing, PR China, September 2014.
- 56) **MU Mondelli.** Hepatorenal syndrome and bacterial infections. Joint Postgraduate Course International Association for the Study of the Liver/Chinese Medical Association, Beijing, PR China, September 2014.
- 57) **MU Mondelli.** Hepatitis E Virus. ESCMID Postgraduate Education Course: Infectious Diseases in the Mediterranean and the Middle East: Current Challenges. Izmir, Turkey, September 2014.

- 58) **MU Mondelli.** Treatment of hepatitis C: the future. Semana Panamericana de las Enfermedades Digestivas, Buenos Aires, October 2014.
- 59) **MU Mondelli.** Hepatitis B: new challenges for an old virus (plenary lecture). Semana Panamericana de las Enfermedades Digestivas, Buenos Aires, October 2014.
- 60) **MU Mondelli.** HCV: new treatment options – DAA & interferon. Teheran Hepatitis Conference. May 2015.
- 61) **MU Mondelli.** Fibrosis regression after cure of hepatitis C? ECCMID symposium Management of chronic viral hepatitis, Copenhagen, April 2015.
- 62) **MU Mondelli.** How to write a scientific article. Seminar at the University of Malaga, Spain. November 2015.
- 63) **MU Mondelli.** What can we learn from anti-viral immunity for autoimmunity? 1st Swiss Autoimmune Liver Disease Meeting. Lugano May 2016.
- 64) **MU Mondelli.** Natural history of HCV infection- what is the impact of untreated disease. ESCMID PGEC "Challenges in management of viral hepatitis", Cavtat, Croatia.
- 65) **MU Mondelli.** Treatment of HCV genotype 1 and 4. Teheran Hepatitis Conference. September 2017.
- 66) **MU Mondelli.** Innate Immunity to HCV. Teheran Hepatitis Conference. September 2017.
- 67) **MU Mondelli.** HEV: One coin two faces. Teheran Hepatitis Conference. September 2017.
- 68) **MU Mondelli.** Residual problems after HCV cure. 11th Annual PSSLD Meeting, Islamabad, Pakistan, December 2017.
- 69) **MU Mondelli.** Simplifying the Screening and Linkage to Care Algorithms for HCV. 11th Annual PSSLD Meeting, Islamabad, Pakistan, December 2017.

Ongoing International collaborations:

Professor Salim Khakoo, University of Southampton, UK.

Professor Francesco Negro, University of Geneva, CH.

Professor Dieter Glebe, University of Giessen, D.

Professor Philippe Roingard. Université F. Rabelais, Tours, France.

Professor Stephen Locarnini. Victorian Infectious Diseases Reference Laboratory, Melbourne Australia.

7. Academic supervision

During the 20 years of my academic career I have supervised several medical students and scientists to obtain MSc, MD and PhD degrees in their research projects leading to development of a thesis. This is part of my academic commitments which can be verified through the offices of the University of Pavia.

8. Teaching activities

As a full professor of infectious diseases I have teaching commitments to undergraduate and graduate students in the English-taught Harvey Course of Medicine and departmental meetings in the Medical School, Faculty of Medicine of the University of Pavia for no less than 350 hours per year. I am Director of the Postgraduate Training School of Infectious and Tropical Diseases of the University of Pavia and provide formal teaching and supervision to trainees in infectious diseases, microbiology, tropical medicine, gastroenterology and internal medicine and I participate in the annual assessment of students. I am the clinical coordinator of the biotechnology course with teaching commitments also there. This activity accounts for approximately 20% of my time. I am Past President of the Infectious Diseases Section of the European Union of Medical Specialists (UEMS-ID) the mission of which is to harmonise higher specialist training in infectious diseases in Europe through the preparation of a curriculum, as well as on training and final assessments.

9. Clinical Commitments

My current appointment as Honorary Consultant Physician in Infectious Diseases and Director of the Research Laboratories, Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy entails weekly outpatient clinics, including a dedicated General Hepatology and Viral Hepatitis Clinic. Clinical commitments include inpatient care on a rotation basis supervising the work of junior staff members for a total of approximately 40% of my time. I have introduced and established up-to date management protocols for patients with viral hepatitis within Fondazione IRCCS Policlinico San Matteo. This includes the use of the most advanced therapies, including novel directly acting antiviral agents (DAAs) for hepatitis C, and the organization of phase 1B to 4 clinical trials.

As a Director of the Research Laboratories I am responsible of 1 Scientist/Laboratory Manager, 1 staff PhD and 3 MSc scientists, and 1 technician under non-tenured contracts paid by research grants. I also have one part-time personal assistant with extensive editorial training and account keeping experience.

10. Research Interests:

My research work focuses predominantly on viral hepatitis. The specific aims are to define the mechanisms of host immune control of hepatitis B virus (HBV) and hepatitis C virus (HCV) replication and the pathogenesis of liver damage triggered by these viruses. By combining a strong personal involvement in laboratory science (immunology in particular), together with clinical management of patients, my research projects have moved from bedside to bench and back again. Currently, I am head of the Division of Infectious Diseases and Immunology in the Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo and Full Professor of Infectious Diseases in the Department of Internal Medicine and Therapeutics of the University of Pavia with Consultant function.

My laboratory research group has a longstanding tradition of research into immunopathogenetic mechanisms of viral hepatitis, particularly HCV and HBV.

The recognition of my international research profile is evident from the list of publications and invited lectures in Europe, Asia, the Americas and international scientific collaborations. I have extensive international experience having served in a variety of scientific committees in prominent positions. I have participated in numerous expert panels and advisory boards.

LIST OF PUBLICATIONS.

A) ORIGINAL (PEER REVIEWED) ARTICLES

- 1) Eddleston ALWF, **Mondelli M**, Mieli-Vergani G, Williams R. Lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection. *Hepatology* 1982;2:122S-7S.
- 2) **Mondelli M**, Mieli-Vergani G, Alberti A, Vergani D, Portmann B, Eddleston ALWF, Williams R. Specificity of T-lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. *J Immunol* 1982;129:2773-8.
- 3) Naumov NV, **Mondelli M**, Alexander GJM, Tedder RS, Eddleston ALWF, Williams R. Relationship between expression of HBV antigens in isolated hepatocytes and autologous lymphocyte cytotoxicity in patients with chronic HBV infection. *Hepatology* 1984;4:63-8.
- 4) **Mondelli M**, Mieli-Vergani G, Eddleston ALWF, Williams R, Mowat AP. Lymphocyte cytotoxicity to autologous hepatocytes in α_1 - antitrypsin deficiency. *Gut* 1984;25:1044-9.
- 5) Bianchi PA, **Mondelli M**, Quarto di Palo F, Ranzi T. Cyclosporin for Crohn's disease. *Lancet* 1984;i:1242 (letter).
- 6) **Mondelli M**, Mieli-Vergani G, Bortolotti F, Cadrobbi P, Portmann B, Alberti A, Realdi G, Eddleston ALWF, Mowat AP. Different mechanisms responsible for cell-mediated cytotoxicity to autologous hepatocytes in children with autoimmune and HBsAg positive chronic liver disease. *J Pediatr* 1985;106:899-906.
- 7) **Mondelli M**, Alberti A, Tremolada F, Williams R, Eddleston ALWF, Realdi G. In vitro cell-mediated cytotoxicity for autologous liver cells in chronic non-A, non-B hepatitis. *Clin Exp Immunol* 1986;63:147-55.
- 8) Alexander GJM, **Mondelli M**, Naumov NV, Nouri-Aria KT, Lowes D, Vergani D, Eddleston ALWF, Williams R. Functional characterization of peripheral blood mononuclear cells in chronic hepatitis B. *Clin Exp Immunol* 1986;63:498-507.
- 9) Chemello L, **Mondelli M**, Bortolotti F, Schiavon E, Pontisso P, Alberti A, Rondanelli EG, Realdi G. Natural killer activity in acute viral hepatitis. *Clin Exp Immunol* 1986;64:59-64.

- 10) **Mondelli M**, Alberti A, Rondanelli EG, Realdi G, Eddleston ALWF. α -interferon enhances non-T cell cytotoxicity for autologous hepatocytes in acute and chronic HBV infection. *J Hepatol* 1986;3:S279-S281.
- 11) **Mondelli M**, Tedder RS, Ferns B, Pontisso P, Realdi G, Alberti A. Differential distribution of hepatitis B core and e antigens in hepatocytes: analysis by monoclonal antibodies. *Hepatology* 1986;6:199-204.
- 12) **Mondelli MU**, Alberti A, Realdi G, Rondanelli EG. In vitro effect of lymphoblastoid α -interferon on subpopulations of effector cells mediating cytotoxicity for autologous hepatocytes in hepatitis B and non-A, non-B. *Int J Immunopharmac* 1986;8:887-91.
- 13) **Mondelli MU**, Bortolotti F, Pontisso P, Rondanelli EG, Williams R, Realdi G, Alberti A, Eddleston ALWF. Definition of hepatitis B virus (HBV)-specific target antigens recognized by cytotoxic T cells in acute HBV infection. *Clin Exp Immunol* 1987;68:242-50.
- 14) Ferrari C, **Mondelli MU**, Penna A, Fiaccadori F, Chisari FV. Functional characterization of cloned intrahepatic, hepatitis B virus nucleoprotein-specific helper T-cell lines. *J Immunol* 1987;139:539-44.
- 15) Vergani D, Mieli-Vergani G, **Mondelli M**, Portmann B, Eddleston ALWF. Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. *Liver* 1987;7:307-15.
- 16) Ceroni M, Minoli L, Di Perri G, Senaldi G, Marone P, Achilli G, **Mondelli MU**, Camana C. Detection of HTLV-III specific IgG in the CSF from a patient with AIDS and encephalitis. *Neurology* 1988;38:143-4.
- 17) Ferrari C, Chisari FV, Ribera E, Penna A, **Mondelli MU**. Functional modulation of hepatitis B core antigen-specific T lymphocytes by an autoreactive T cell clone. *J Immunol* 1988;141:1155-60.
- 18) Raney AK, Milich DR, Hughes JL, Sorge J, Chisari FV, **Mondelli MU**, McLachlan A. Retroviral-mediated transfer and expression of hepatitis B e antigen in human skin fibroblasts and Epstein-Barr virus-transformed B lymphocytes. *Virology* 1989;168:31-9.
- 19) **Mondelli MU**, Barbarini G, Carugno B, Rondanelli EG. Absence of antibodies to human immunodeficiency virus in long-term institutionalized psychiatric patients. *Eur J Epidemiol* 1989;5:263-4 (letter).
- 20) Dussaix E, Maggiore G, De Giacomo C, **Mondelli M**, Martres P, Alvarez F. Autoimmune hepatitis in children and hepatitis C virus testing. *Lancet* 1990;335:1160-1 (letter).
- 21) **Mondelli MU**, Cristina G, Filice G, Rondanelli EG, Piazza V, Barbieri C. Anti-HCV positive patients in dialysis units? *Lancet* 1990;336:244 (letter).
- 22) **Mondelli MU**. Effect of interleukin-4 on cytolytic T cells. *Int J Immunopathol Pharmacol* 1991;4:39-45.

- 23) **Mondelli MU**, Smedile V, Piazza V, Villa G, Barbieri C, Gattarello G, Mancini F, Raimondo G. Abnormal alanine aminotransferase activity reflects exposure to hepatitis C virus in haemodialysis patients. *Nephrol Dial Transplant* 1991;6:480-3.
- 24) Cerino A, **Mondelli MU**. Identification of an immunodominant B-cell epitope on the hepatitis C virus non structural region defined by human monoclonal antibodies. *J Immunol* 1991;147:2692-6.
- 25) **Mondelli MU**, Cristina G, Piazza V, Cerino A, Villa G, Salvadeo A. High prevalence of antibodies to hepatitis C virus in haemodialysis units using a 2nd generation assay. *Nephron* 1992;61:350-1.
- 26) de Lalla C, Cerino A, Rosa C, Griva S, Bonelli F, **Mondelli MU**. Properties of a human monoclonal antibody specific for the hepatitis C virus NS4 region. *J Hepatol* 1993;18:163-7.
- 27) Maccabruni A, Caselli D, **Mondelli M**, Degioanni M, Cerino A. Vertical transmission of hepatitis C virus and HIV. *AIDS* 1993;7:1024-5 (letter).
- 28) Silini E, Bono F, Cerino A, Piazza V, Solcia E, **Mondelli MU**. Virological features of HCV infection in hemodialysis patients. *J Clin Microbiol* 1993;31:2913-7.
- 29) Cerino A, Boender P, Rosa C, La Monica N, Habets W, **Mondelli MU**. A human monoclonal antibody specific for the N-terminus of hepatitis C virus nucleocapsid protein. *J Immunol* 1993;151:7005-15.
- 30) González-Peralta RP, Fang JWS, Davis GL, Gish R, Tsukiyama-Kohara K, Kohara M, **Mondelli MU**, Lesniewski R, Phillips MI, Mizokami M, Lau JYN. Optimization for the detection of hepatitis C virus (HCV) antigens in the liver. *J Hepatol* 1994;20:143-7.
- 31) **Mondelli MU**, Cerino A, Boender P, Oudshoorn P, Middeldorp J, Fipaldini C, La Monica N, Habets W. Significance of the immune response to a major, conformational B cell epitope on the hepatitis C virus NS3 region defined by a human monoclonal antibody. *J Virol* 1994;68:4829-36.
- 32) **Mondelli MU**, Cerino A, Bono F, Cividini A, Malfitano A, Maccabruni A, Barbarini G, Aricò M, Piazza V, Minoli L, Silini E. Hepatitis C virus (HCV) core serotypes in chronic HCV infection. *J Clin Microbiol* 1994;32:2523-7.
- 33) Aricò M, Maggiore G, Silini E, Bono F, Viganò C, Cerino A, **Mondelli MU**. Hepatitis C virus infection in children treated for acute lymphoblastic leukemia. *Blood* 1994;84:2919-22.
- 34) Silini E, Bono F, Cividini A, Cerino A, Bruno S, Rossi S, Belloni G, Brugnetti B, Civardi E, Salvaneschi L, **Mondelli MU**. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. *Hepatology* 1995;21:285-90.
- 35) Maggiore G, Ventura A, De Giacomo C, Silini E, Cerino A, **Mondelli MU**. Vertical transmission of hepatitis C. *Lancet* 1995;345:1122 (letter).

- 36) Silini E, Bono F, Cividini A, Cerino A, Bruno S, Maccabruni A, Tinelli C, Bellobuono A, **Mondelli MU**. Molecular epidemiology of hepatitis C virus infection in intravenous drug users. *J Hepatol* 1995;22:691-5.
- 37) Scarselli E, Cerino A, Esposito G, Silini E, **Mondelli MU**, Traboni C. Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (E2; gp70) hypervariable region 1 in hepatitis C viremic patients. *J Virol* 1995;69:4407-12.
- 38) Maccabruni A, Bossi G, Caselli D, Cividini A, Silini A, **Mondelli MU**. High efficiency of transmission of hepatitis C virus among babies born to human immunodeficiency virus-negative women. *Pediatr Infect Dis J* 1995;14:921-2 (letter).
- 39) Esposito G, Scarselli E, Cerino A, **Mondelli MU**, La Monica N, Traboni C. A human antibody specific for the hepatitis C virus core protein: expression in a bacterial system and characterization. *Gene* 1995;164:203-9.
- 40) González-Peralta RP, Fang JWS, Davis GL, Gish RG, Kohara M, **Mondelli MU**, Urdea MS, Mizokami M, Lau JYN. Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C. *Digest Dis Sci* 1995;40:2595-601.
- 41) Gane EJ, Naoumov NV, Qian K-P, **Mondelli MU**, Maertens G, Portmann BC, Lau JYN, Williams R. A longitudinal analysis of hepatitis C virus replication following liver transplantation. *Gastroenterology* 1996;110:167-77.
- 42) Cerino A, Cividini A, Asti M, Lanza A, Silini E, **Mondelli MU**. Comparative evaluation of two serologic typing methods of hepatitis C virus. *J Clin Microbiol* 1996;34:714-6.
- 43) Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, Bono F, Iamoni G, Tinelli C, **Mondelli MU**, Ideo G. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. *Gastroenterology* 1996;111:199-205.
- 44) Cerino A, Bissolati M, Cividini A, Nicosia A, Esumi M, Hayashi N, Mizuno K, Slobbe R, Oudshoorn P, Silini E, Asti M, **Mondelli MU**. Antibody responses to the hepatitis C virus (HCV) E2 protein: relationship to viraemia and prevalence in anti-HCV seronegative subjects. *J Med Virol* 1997;51:1-5.
- 45) Esposito G, Morea V, Scarselli E, Cerino A, **Mondelli MU**, La Monica N, Traboni C. Recombinant human antibodies specific for hepatitis C virus proteins. *Arch Virol* 1997;142:601-10.
- 46) Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M, **Mondelli MU**. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. *Hepatology* 1997;25:754-8.
- 47) Tafi R, Bandi R, Prezzi C, **Mondelli MU**, Cortese R, Monaci P, Nicosia A. Identification of HCV core mimotopes: improved methods for the selection and use of disease-related phage-displayed peptides. *Biol Chem* 1997;378:495-502.
- 48) Cividini A, Pistorio A, Regazzetti A, Cerino A, Tinelli C, Mancuso A, Ribola M, Galli ML, Agnusdei A, Leone M, Silini E, **Mondelli MU**. Hepatitis C virus infection among

institutionalized psychiatric patients: a regression analysis of indicators of risk. *J Hepatol* 1997;27:455-63.

- 49) Cristina G, Piazza V, Efficace E, Poggio F, Pasotti N, Martino G, Cividini A, Salvadeo A, **Mondelli MU**. A survey of hepatitis C virus infection in haemodialysis patients over a 7-year follow-up. *Nephrol Dial Transplant* 1997;12:2208-10.
- 50) Zavaglia C, Martinetti M, Silini E, Bottelli R, Daielli C, Asti M, Salvaneschi L, **Mondelli MU**, Ideo G. Association between class II alleles and protection or susceptibility to chronic hepatitis C. *J Hepatol* 1998;28:1-7.
- 51) Brambilla S, Bellati G, Asti M, Lisa A, Candusso ME, D'Amico M, Grassi G, Giacca M, Franchini A, Bruno S, Ideo G, **Mondelli MU**, Silini E. Dynamics of hypervariable region 1 (HVR1) variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. *Hepatology* 1998;27:1678-86.
- 52) Puntoriero G, Meola A, Lahm A, Zucchelli S, Bruno B, Tafi R, Pezzanera M, **Mondelli MU**, Cortese R, Tramontano A, Galfrè G, Nicosia A. Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. *EMBO J* 1998;17:3521-33.
- 53) Silini E, Belli L, Alberti AB, Asti M, Cerino A, Bissolati M, Rondinara G, De Carlis L, Forti D, **Mondelli MU**, Ideo G. HGV/GBV-C infection in liver transplant recipients. Antibodies to the viral E2 envelope glycoprotein protect from *de novo* infection. *J Hepatol* 1998;29:533-40.
- 54) Maggiore G, Caprai S, Cerino A, Silini E, **Mondelli MU**. Antibody-negative chronic hepatitis C virus infection in immunocompetent children. *J Pediatr* 1998;132:1048-50.
- 55) **Mondelli MU**, Zorzoli I, Cerino A, Cividini A, Bissolati M, Segagni L, Perfetti V, Anesi E, Garini P, Merlini GP. Clonality and specificity of cryoglobulins associated with HCV: pathophysiological implications. *J Hepatol* 1998;29:879-86.
- 56) Aricò M, Bissolati M, Bossi G, Asti M, Cerino A, Caselli D, Ricci A, Klersy C, Silini E, **Mondelli MU**. GB virus C infection in patients treated for childhood acute lymphoblastic leukemia. *Transfusion* 1999;39:212-7.
- 57) Negro F, Krawczynski K, Quadri R, Rubbia-Brandt L, **Mondelli MU**, Zarski J-P, Hadengue A. Detection of genomic and minus strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semi-quantitative RT-PCR. *Hepatology* 1999;29:536-42.
- 58) Piazza V, Cristina G, Montagna G, Galli F, Ungaretti M, Martino G, Cividini A, Salvadeo A, **Mondelli MU**. Long-term persistence of hepatitis C viremia in hemodialysis patients. *Clin Nephrol* 1999;51:129-30.
- 59) Asti M, Martinetti M, Zavaglia C, Cuccia M, Gusberti L, Tinelli C, Cividini A, Bruno S, Salvaneschi L, Ideo G, **Mondelli MU**, Silini E. HLA class II and III and severity of hepatitis C virus (HCV)-related chronic liver disease. *Hepatology* 1999;29:1272-9.

- 60) Osella AR, Sonzogni L, Cavallini A, Foti L, Guerra V, Di Leo A, **Mondelli MU**, Misciagna G, Silini EM. Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in Southern Italy: a population-based study. *J Clin Microbiol* 1999;37:2371-2.
- 61) **Mondelli MU**, Cerino A, Lisa A, Brambilla S, Segagni L, Cividini A, Bissolati M, Missale G, Bellati G, Meola A, Bruniercole B, Nicosia A, Galfrè G, Silini E. Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation. *Hepatology* 1999;30:537-45.
- 62) Romeo R, Rumi MG, Donato MF, Cargnel MA, Viganò P, **Mondelli MU**, Cesana B, Colombo M. Hepatitis C is more severe in drug users with human immunodeficiency virus infection. *J Vir Hepat* 2000;7:297-301.
- 63) Raimondo G, Balsano C, Craxì A, Farinati F, Levrero M, **Mondelli MU**, Pollicino C, Squadrito G, Tiribelli C. Occult hepatitis B virus infection. *Dig Liver Dis* 2000;32:822-6.
- 64) **Mondelli MU**. Neonatal blood microtransfusions and hepatitis C virus infection. *Lancet* 2001;357:1363 (Letter).
- 65) Osella AR, Misciagna G, Elba S, Buongiorno G, Cavallini A, Di Leo A, Sonzogni L, **Mondelli MU**, Silini EM. Hepatitis C virus genotypes and risk of cirrhosis in Southern Italy. *Clin Infect Dis* 2001;33:70-5.
- 66) Piazza V, Montagna G, Galli F, Efficace E, Boselli E, Cristina G, Salvadeo A, **Mondelli MU**. Risk of exposure to hepatitis B and C viruses in hemodialysis patients: a 10-year survey. *Clin Nephrol* 2001;56:252-4 (Letter).
- 67) Cividini A, Rebucci C, Silini E, **Mondelli MU**. Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign? *Gastroenterology* 2001;121:1526-7 (Letter).
- 68) Cerino A, Meola A, Segagni L, Furione M, Triyatni M, Liang TJ, Nicosia A, **Mondelli MU**. Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles *J Immunol* 2001;167:3878-3886.
- 69) Roccasecca R, Folgori A, Ercole BB, Puntoriero G, Lahm A, Zucchelli S, Tafi R, Pezzanera M, Galfrè G, Tramontano A, **Mondelli MU**, Pessi A, Nicosia A, Cortese R, Meola A. Mimotopes of the hypervariable region 1 of the hepatitis C virus induce cross-reactive antibodies directed against discontinuous epitopes. *Mol Immunol* 2001;38:485-92.
- 70) Sonzogni L, Silvestri L, De Silvestri A, Gritti C, Foti L, Zavaglia C, Battelli R, **Mondelli MU**, Civardi E, Silini EM. Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. *Hepatology* 2002;36:195-201.
- 71) Sullivan DE, **Mondelli MU**, Curiel DT, Krasnykh V, Mikheeva G, Gaglio P, Morris CB, Dash S, Gerber MA. Construction and characterization of an intracellular single-chain human antibody to hepatitis C virus non-structural 3 protein. *J Hepatol* 2002;37:660-8.

- 72) Silvestri L, Sonzogni L, De Silvestri A, Gritti C, Foti L, Zavaglia C, Leverì M, Cividini A, **Mondelli MU**, Civardi E, Silini EM. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. *Int J Cancer* 2003;104:310-7.
- 73) Cividini A, Cerino A, Muzzi A, Furione M, Rebucci C, Segagni L, Gatti M, Barnaba V, **Mondelli MU**. Kinetics and significance of serum hepatitis C virus core antigen in patients with acute hepatitis C. *J Clin Microbiol* 2003;41:2144-6.
- 74) Rebucci C, Cerino A, Cividini A, Timo L, Furione M, **Mondelli MU**. Monitoring response to antiviral therapy in patients with chronic hepatitis C virus infection by a core antigen assay. *J Clin Microbiol* 2003;41:3881-4.
- 75) Rossi L, Levreri M, Gritti C, De Silvestri A, Zavaglia C, Sonzogni L, Silvestri L, Civardi E, **Mondelli MU**, Silini EM. Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients. *J Hepatol* 2003;39:564-70.
- 76) Francavilla V, Accapezzato D, De Salvo M, Rawson P, Cosimi O, Lipp M, Cerino A, Cividini A, **Mondelli MU**, Barnaba V. Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms. *Eur J Immunol*, 2004;34:427-37.
- 77) Accapezzato D, Francavilla V, Rawson P, Cerino A, Cividini A, **Mondelli MU**, Barnaba V. Subversion of CD8+ T cell differentiation in acute hepatitis C virus infection: the role of the virus. *Eur J Immunol*, 2004;34:438-46.
- 78) Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, Abrignani S, **Mondelli MU**, Barnaba V. Hepatic expansion of a virus-specific regulatory CD8+T cell population in chronic hepatitis C virus infection. *J Clin Invest* 2004;113:963-72.
- 79) Levreri, M, Gritti C, Rossi L, Zavaglia C, Civardi E, **Mondelli MU**, De Silvestri A, Silini E. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. *Cancer Lett* 2004;208:75-9.
- 80) Furione M, Maserati R, Gatti M, Baldanti F, Cividini A, Bruno R, Gerna G, **Mondelli MU**. Dissociation between serum and liver hepatitis C virus RNA levels in patients coinfecting with human immunodeficiency virus. *J Clin Microbiol* 2004;42:3012-6.
- 81) Bruno S, Cammà C, Di Marco V, Di Bona D, Rumi MG, Vinci M, Rebucci C, Colombo M, Craxì A, **Mondelli MU**, Pinzello GB. Peginterferon alfa2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. *J Hepatol* 2004;41:474-81.
- 82) Spada E, Mele A, Berton A, Ruggeri L, Ferrigno L, Garbuglia AR, Perrone MP, Girelli G, Del Porto P, Piccolella E, **Mondelli MU**, Amoroso P, Cortese R, Nicosia A, Vitelli A, Folgori A. Multi-specific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. *Gut* 2004;53:1673-81.

- 83) Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Malinverni R, Dufour J-F, Helbling B, Hadengue A, Gonvers J-J, Müllhaupt B, Cerny A, **Mondelli MU**, Negro F, for the Swiss Hepatitis C Cohort Study (SCCS). Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. *J Hepatol* 2005;42:41-6.
- 84) Accapezzato D, Visco V, Francavilla V, Molette C, Donato T, Paroli M, **Mondelli MU**, Doria M, Torrisi MR, Barnaba V. Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. *J Exp Med*. 2005;202:817-28.
- 85) Cammà C, Bruno S, Di Marco V, Di Bona D, Rumi M, Vinci M, Rebucci C, Cividini A, Pizzolanti G, **Mondelli MU**, Colombo M, Pinzello G, Craxì A. Insulin resistance is associated with steatosis in non-diabetic patients with genotype 1 chronic hepatitis C. *Hepatology* 2006;43:64-71.
- 86) Bianchettin G, Bonaccini C, Oliva R, Tramontano A, Cividini A, Casato M, Merlini G, Silini E, **Mondelli MU**. Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls. *J Virol* 2007; 81:4564-71.
- 87) Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, **Mondelli MU**. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in cirrhotic patients: a seventeen-year, prospective cohort study. *Hepatology* 2007; 46:1350-1356.
- 88) Ferraro D, Giglio M, Bonura C, Di Marco V, **Mondelli MU**, Craxì A, Di Stefano R. Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay. *J Vir Hepat* 2008; 15:66-70.
- 89) Raimondo G, Allain J-P, Brunetto MR, Buendia MA, Chen D-S, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, **Mondelli MU**, Pawlotsky J-M, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trepo C, Villa E, Will H, Zanetti AR, Zoulim F. Statements from the *Taormina* expert meeting on occult hepatitis B virus infection. *J Hepatol* 2008; 49:652-7.
- 90) Varchetta S, Oliviero B, Donato MF, Agnelli F, Rigamonti C, Paudice E, Arosio E, Berra M, Rossi G, Tinelli C, Fagnoni FF, Colombo M, Mavilio D, **Mondelli MU**. Prospective study of natural killer cell phenotype in recurrent hepatitis C virus infection following liver transplantation: *J Hepatol* 2009;50:314-22.
- 91) Franceschini D, Paroli M, Francavilla V, Videtta M, Morrone S, Labbadia G, Cerino A, **Mondelli MU**, Barnaba V. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. *J Clin Invest* 2009;119:551-64.
- 92) Raimondi S, Bruno S, **Mondelli MU**, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. *J Hepatol* 2009;50:1142-54.
- 93) Oliviero B, Varchetta, Paudice E, Cerino A, Michelone G, Zaramella M, Mavilio D, De Filippi F, Bruno S, **Mondelli MU**. Natural killer cell functional dichotomy in chronic

hepatitis B and chronic hepatitis C virus infections. *Gastroenterology* 2009;137:1151-60.

- 94) Oliviero B, Cerino A, Varchetta S, Paudice E, Pai S, Ludovisi S, Zaramella M, Michelone G, Pugnale P, Negro F, Barnaba V, **Mondelli MU**. Enhanced B cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. *J Hepatol* 2011;55:53-60.
- 95) Visentini M, Ludovisi S, Petrarca A, Pulvirenti F, Zaramella M, Monti M, Conti V, Ranieri J, Colantuono S, Fognani E, Piluso A, Tinelli C, Zignego AL, **Mondelli MU**, Fiorilli M, Casato M. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. *Autoimmun Rev.* 2011;10:714-9.
- 96) Ferraioli G, Tinelli C, Malfitano A, Dal Bello B, Filice G, Filice C; Liver Fibrosis Study Group, Above E, Barbarini G, Brunetti E, Calderon W, Di Gregorio M, Lissandrin R, Ludovisi S, Maiocchi L, Michelone G, **Mondelli M**, Patruno SF, Perretti A, Poma G, Sacchi P, Zaramella M, Zicchetti M. Performance of real-time strain elastography, transient elastography, and aspartate-to-platelet ratio index in the assessment of fibrosis in chronic hepatitis C. *AJR Am J Roentgenol.* 2012;199:19-25.
- 97) Varchetta S, Mele D, Mantovani S, Oliviero B, Cremonesi E, Ludovisi S, Michelone G, Alessiani M, Rosati R, Montorsi M, **Mondelli MU**. Impaired intrahepatic natural killer cell function in chronic hepatitis C virus infection. *Hepatology* 2012;56:841-9.
- 98) Pianko S, Zeuzem S, Chuang WL, Foster GR, Sarin SK, Flisiak R, Lee CM, Andreone P, Piratvisuth T, Shah S, Sood A, George J, Gould M, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Li Y, Pang M, Yin Y, Feutren G, Jacobson IM; **B2202 Study Team**. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. *J Viral Hepat.* 2012;19:623-34.
- 99) Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C; **Liver Fibrosis Study Group**. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. *Hepatology.* 2012;56:2125-33.
- 100) Varchetta S, Brunetta E, Roberto A, Mikulak J, **Mondelli MU**, Mavilio D. Engagement of Siglec-7 receptor induces a pro-inflammatory response selectively in monocytes. *PLoS ONE* 2012;7:e45821.
- 101) Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Lissandrin R, Filice G, Filice C, Above E, Barbarini G, Brunetti E, Calderon W, Di Gregorio M, Gulminetti R, Lanzarini P, Ludovisi S, Maiocchi L, Malfitano A, Michelone G, Minoli L, **Mondelli M**, Novati S, Patruno SF, Perretti A, Poma G, Sacchi P, Zanaboni D, Zaramella M. Performance of liver stiffness measurements by transient elastography in chronic hepatitis. *World J Gastroenterol.* 2013;19:49-56.
- 102) Varchetta S, Oliviero B, Mavilio D, **Mondelli MU**. Different combinations of cytokines and activating receptor engagement are required for human natural killer cell functional diversity. *Cytokine* 2013;62:58-63.

- 103) Oliviero B, Mele D, Degasperi E, Aghemo A, Cremonesi E, Rumi MG, Tinelli C, Varchetta S, Mantovani S, Colombo M, **Mondelli MU**. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic hepatitis C virus infection. *J Hepatol* 2013;59:38-44.
- 104) Di Marco V, Covolo L, Levrero M, Puoti M, Suter F, Gaeta GB, Ferrari C, Raimondo G, Fattovich G, Santantonio T, Alberti A, Bruno R, Mussini C, **Mondelli M**, Donato F, Craxì A. Who is more likely to respond to dual treatment with PEG-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. *J Viral Hepat* 2013;20:790-800.
- 105) Varchetta S, Lusso P, Hudspeth K, Mikulak J, Mele D, Paolucci S, Cimbri R, Malnati M, Riva A, Maserati R, **Mondelli MU**, Mavilio D. Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4pos T cells and macrophages. *Retrovirology* 2013;10:154.
- 106) Fagioli S, Colli A, Bruno R, Burra P, Craxì A, Gaeta GB, Grossi P, **Mondelli M**, Puoti M, Sagnelli E, Stefani S, Toniutto P. Management of infections in cirrhotic patients: Report of a Consensus Conference. *Dig Liver Dis* 2014;46:204-12.
- 107) Fagioli S, Colli A, Bruno R, Craxì A, Gaeta GB, Grossi P, **Mondelli MU**, Puoti M, Sagnelli E, Stefani S, Toniutto P, Burra P; for the 2011 AISF Single Topic Group. Management of infections pre- and post-liver transplantation: Report of a AISF Consensus Conference. *J Hepatol* 2014;60:1075-89.
- 108) Colombatto P, Brunetto MR, Maina AM, Romagnoli V, Almasio P, Rumi MG, Ascione A, Pinzello G, **Mondelli M**, Muratori L, Rappuoli R, Rosa D, Houghton M, Abrignani S, Bonino F. HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFN α 2a and Ribavirin: a randomized controlled trial. *J Viral Hepat* 2014;21:458-65.
- 109) Oliviero B, Mantovani S, Ludovisi S, Varchetta S, Mele D, Paolucci S, Baldanti F, **Mondelli MU**. Skewed B cells in chronic hepatitis C virus infection maintain their ability to respond to virus-induced activation. *J Viral Hepat* 2015;22:391-8.
- 110) Cerino A, Bremer CM, Glebe D, **Mondelli MU**. A human monoclonal antibody against hepatitis B surface antigen with potent neutralizing activity. *PLoS ONE* 2015;10:e0125704.
- 111) Visentini M, Tinelli C, Colantuono S, Monti M, Ludovisi S, Gragnani L, Mitrevski M, Ranieri J, Fognani E, Piluso A, Granata M, **Mondelli MU**, Zignego AL, Fiorilli M, Casato M. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. *Autoimmun Rev* 2015;14:889-96.
- 112) Lombardi A, Landonio S, Magni C, Cheli S, Mazzali C, Mondelli MU, Rizzardini G, Clementi E, Falvella FS. ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors. *Pharmacology* 2015;96:163-6.

- 113) Mantovani S, Mele D, Oliviero B, Barbarini G, Varchetta S, **Mondelli MU**. NKp30 isoforms in patients with chronic hepatitis C virus infection. *Immunology* 2015;146:234-42
- 114) Özaras R, Corti G, Ruta S, Lacombe K, **Mondelli MU**, Irving W, Puoti M, Khalighi A, Santos L, Harxhi, Lazarevic I, Soriano V, Gervain J, Leblebicioglu H, Salmon D, Arends J. Differences in Availability of Diagnostics and Treatment Modalities for Chronic Hepatitis B Across Europe. *Clin Microbiol Infect* 2015;21:1027-32.
- 115) Varchetta S, Mele D, Lombardi A, Oliviero B, Mantovani S, Tinelli C, Spreafico M, Prati D, Ludovisi S, Ferraioli G, Filice C, Aghemo A, Lampertico P, Facchetti F, Bernuzzi F, Invernizzi P, **Mondelli MU**. Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. *Gut* 2016;65:1998-2006.
- 116) Mele D, Mantovani S, Oliviero B, Grossi G, Ludovisi S, **Mondelli MU**, Varchetta S. Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7. *Antiviral Res* 2017;137:108-111.
- 117) Paolucci S, Premoli M, Ludovisi S, **Mondelli MU**, Baldanti F. HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy. *Antivir Ther* 2017;22:365-368.
- 118) Oliviero B, Mantovani S, Varchetta S, Mele D, Grossi G, Ludovisi S, Nuti E, Rossello A, **Mondelli MU**. Hepatitis C virus-Induced NK Cell Activation Causes Metzincin-Mediated CD16 Cleavage and Impaired Antibody-Dependent Cytotoxicity. *J Hepatol* 2017;66:1130–1137.
- 119) Mele D, Mantovani S, Oliviero B, Grossi G, Lombardi A, **Mondelli MU**, Varchetta S. Monocytes inhibit hepatitis C virus-induced TRAIL expression in CD56^{bright} NK cells. *J Hepatol*. 2017;67:1148–1156.
- 120) Paolucci S, Premoli M, Novati S, Gulminetti R, Maserati R, Barbarini G, Sacchi P, Piralla A, Sasseria D, De Marco L, Girello A, **Mondelli MU**, Baldanti F. Baseline and breakthrough resistance mutations in HCV patients failing DAAs. *Sci Rep*. 2017;7:16017.
- 121) Mele D, Bossi G, Maggiore G, Oliviero B, Mantovani S, Bonelli B, **Mondelli MU**, Varchetta S. Altered natural killer cell cytokine profile in type 2 autoimmune hepatitis. *Clin Immunol* 2018;188:31–37.

B) EDITORIALS AND INVITED REVIEWS

- 122) **Mondelli M**, Eddleston ALWF. Lymphocyte cytotoxicity for autologous hepatocytes. *Gut* 1984;25:109-13.
- 123) **Mondelli M**, Eddleston ALWF. Mechanisms of liver cell injury in acute and chronic hepatitis B. *Semin Liver Dis* 1984;4:47-58.

- 124) Eddleston ALWF, **Mondelli M**. Immunopathological aspects of liver cell injury in chronic hepatitis B virus infection. *J Hepatol* 1986;3:S17-S23.
- 125) **Mondelli MU**, Manns M, Ferrari C. Does the immune response play a role in the pathogenesis of chronic liver disease? *Arch Pathol Lab Med* 1988;112:489-97.
- 126) Chisari FV, Ferrari C, **Mondelli MU**. Hepatitis B virus structure and biology. *Microb Pathogen* 1989;6:311-25.
- 127) **Mondelli MU**, Chisari FV, Ferrari C. The cellular immune response to nucleocapsid antigens in hepatitis B virus infection. *Springer Semin Immunopathol* 1990;12:25-32.
- 128) **Mondelli MU**, Colombo M. The emerging picture of hepatitis C. *Dig Dis* 1991;9:245-252.
- 129) **Mondelli MU**, Cerino A, Bellotti V, de Koning A. Immunobiology and pathogenesis of hepatitis C virus infection. *Res Virol* 1993;144:269-74.
- 130) **Mondelli MU**, Cividini A, Cerino A. Role of humoral immune responses in hepatitis B and C virus infections. *Eur J Clin Invest* 1995;25:543-7.
- 131) Silini E, **Mondelli MU**. Significance of hepatitis C virus genotypes. *Vir Hepat Rev* 1995;1:111-20.
- 132) **Mondelli MU**. Is there a role for immune responses in the pathogenesis of hepatitis C? *J Hepatol* 1996; 25:232-8.
- 133) **Mondelli MU**, Silini E. Clinical significance of hepatitis C virus genotypes. *J Hepatol* 1999;31: (Suppl.1) 65-70.
- 134) **Mondelli MU**, Cerino A. Production of human monoclonal antibodies to hepatitis C virus and their characterization. *Methods Mol Med*. 1999;19:451-61.
- 135) Raimondo G, Balsano C, Craxì A, Farinati F, Levrero M, **Mondelli M**, Pollicino T, Squadrito G, Tiribelli C. Occult hepatitis B virus infection. *Dig Liver Dis* 2000;32:822-6.
- 136) **Mondelli MU**. Immunopathogenesis of viral hepatitis. *Clin Rev Allerg Immunol* 2000;18:141-166.
- 137) **Mondelli MU**, Cerino A, Segagni L, Meola A, Cividini A, Silini E, Nicosia A. Hypervariable region 1 (HVR1) of HCV: Immunological decoy or biologically relevant domain? *Antiviral Res* 2001;52:153-9.
- 138) **Mondelli MU**. Immunopathogenesis of viral hepatitis. *Clin Rev Allergy Immunol*. 2000;18:141-66.
- 139) **Mondelli MU**, Cerino A, Meola A, Nicosia A. Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses. *J Biosci* 2003;28:287-304.

- 140) **Mondelli MU**. Natural history of hepatitis C virus infection. *J Biol Regul Homeost Agents* 2003;17:128-32.
- 141) **Mondelli MU**. Hepatitis C virus: simply too smart to be just a liver pathogen. *Dig Liver Dis* 2003;35:760-2.
- 142) **Mondelli MU**. Multifaceted functions of B cells in chronic hepatitis C virus infection. *Antivir Res* 2003;60:111-5.
- 143) **Mondelli MU**. Monitoring response to antiviral treatment by serum hepatitis C virus core antigen: too early to take shortcuts? *J Hepatol* 2004;40:536-8.
- 144) **Mondelli MU**, Cerino A, Cividini A. Acute hepatitis C: diagnosis and management. *J Hepatol*. 2005;42:S108-14.
- 145) **Mondelli MU** and Barnaba V. Viral and host immune regulatory mechanisms in HCV infection. *Eur J Gastroenterol Hepatol*, 2006;18:327-31.
- 146) **Mondelli MU**. Eltrombopag: an effective remedy for thrombocytopenia? *J Hepatol*. 2008;48:1030-2.
- 147) Raimondi S, Maisonneuve P, Bruno S, **Mondelli MU**. Is response to antiviral treatment influenced by hepatitis B virus genotype? *J Hepatol* 2010; 52:441-49.
- 148) **Mondelli MU**, Varchetta S, Oliviero B. Natural killer cells in viral hepatitis: facts and controversies. *Eur J Clin Invest* 2010; 40:851-63.
- 149) **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol*. 2011;55:245-64.
- 150) Bruno S, Savojardo D, Almasio PL, **Mondelli MU**. Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. *Hepat Med* 2011;3:21-8.
- 151) **Mondelli MU**. NKG2D and its ligands: key to immunotherapy of liver cancer? *J Hepatol* 2012;56:308-10.
- 152) **Mondelli MU**, Oliviero B, Mele D, Mantovani S, Gazzabin C, Varchetta S. Natural killer cell functional dichotomy: a feature of chronic viral hepatitis? *Front Immunol* 2012; 3:351.
- 153) **Mondelli MU**. Liver International: between tradition and innovation. *Liver Int*. 2014;34:822.
- 154) **Mondelli MU**. The multifaceted functions of ribavirin: antiviral, immunomodulator, or both? *Hepatology* 2014;60:1126-9.
- 155) **Mondelli MU**. Direct-acting antivirals cure innate immunity in chronic hepatitis C. *Gastroenterology* 2015;149:25–28.

- 156) **Mondelli MU**. Exosomes: multitask cargo carriers modulating innate immunity to viruses. *Cell Mol Immunol* 2017;14:476–477
- 157) Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, Dan YY, Brooks-Rooney C, Negro F, **Mondelli MU**. The impact of hepatitis C virus outside the liver: evidence from Asia. *Liver Int* 2017;37:159–72
- 158) **Mondelli MU**. Natural History of HCV Infection- What Is the Public Health Impact of Untreated Disease? *Future Virol* 2017;12:13-8.
- 159) **Mondelli MU**. Do Liver Mucosa-Associated Invariant T Cells Delay Hepatitis C Progression, or Are They Innocent Bystanders? *Gastroenterology* 2017;153:1185–1187.
- 160) Salmon-Ceron D, **Mondelli MU**, Matičič M, Arends JE and ESCMID Study Group for Viral Hepatitis. The success of HCV cure: every rose has thorns. *J Viral Hepat*. 2018;25:320-328.

C) CHAPTERS IN BOOKS

- 161) **Mondelli M**, Naumov N, Eddleston ALWF. *The immunopathogenesis of liver damage in chronic hepatitis B virus infection*. In: Chisari FV, ed., *Advances in hepatitis research*. Masson Publishing, Inc., New York, 1984;144-51.
- 162) Fiaccadori F, **Mondelli M**, Penna A, Chisari FV, Ferrari C. *Isolation and functional characterization of circulating HBcAg-specific and autoreactive T cell clones in chronic active hepatitis B*. In: Gentilini P, Dianzani MU, eds., *Pathophysiology of the liver*, Elsevier Science Publishers BV, 1988;109-17.
- 163) Ferrari C, Penna A, **Mondelli MU**, Fiaccadori F, Chisari FV. *Intrahepatic HBcAg-specific regulatory T-cell networks in chronic active hepatitis B*. In: *Viral hepatitis and liver disease*. Alan Liss, Inc., New York, 1988;641-4.
- 164) **Mondelli MU**, Parks DE, Chisari FV. *Production and distribution of lymphocytes and plasma cells*. In: Williams WJ, Beutler E, Erslev AJ, Lichtmann MA, eds., *Hematology* 4th edition. McGraw-Hill, New York, 1990;945-9.
- 165) **Mondelli MU**, Cerino A, Bellotti V, de Lalla C, Rosa C, Bonelli F, Habets W. *Production and characterization of a human monoclonal antibody to the hepatitis C virus NS4 region*. In: Terhorst C, Malavasi F, Albertini A (eds): *Generation of Antibodies by Cell and Gene Immobilization*. Year Immunol. Basel, Karger 1993;7:220-6.
- 166) **Mondelli MU**, Cerino A. *Clonal analysis of human lymphocyte-B responses to hepatitis C virus structural and non-structural regions*. In: Meyer zum Büschenfelde K-H, Hoofnagle JH, Manns M, eds. *Immunology and Liver, Proceedings of Falk Symposium No.70*, Kluwer Academic Publishers, Lancaster U.K., 1993;105-14.

- 167) **Mondelli MU**, Negro F. *Immunobiology of hepatitis B and D virus infections*. In: Thomas HC, Waters J, eds., *Immunology of liver disease*. Kluwer Academic Publishers, Dordrecht, The Netherlands, 1994;39-55.
- 168) **Mondelli MU**, Perrillo RP. Workshop: "Clinical significance of virus-specific immune responses". In: Rizzetto M, Purcell RH, Gerin JL, Verme G, Eds., "Viral Hepatitis and Liver Disease", *Proceedings of IX Triennial International Symposium on Viral Hepatitis and Liver Disease*, Rome, Italy, 21-25 April 1996. Edizioni Minerva Medica, Torino, 1997:855-7.
- 169) **Mondelli MU**, Tur-Kaspa R. Poster's summary: "Immunology – Non A-E Hepatitis". In: Rizzetto M, Purcell RH, Gerin JL, Verme G, Eds., "Viral Hepatitis and Liver Disease", *Proceedings of IX Triennial International Symposium on Viral Hepatitis and Liver Disease*, Rome, Italy, 21-25 April 1996. Edizioni Minerva Medica, Torino, 1997:919-20.
- 170) **Mondelli MU**, Cerino A. *Production of anti-HCV by human B cell clones and their characterization*. In: Lau JYN, Ed., "Hepatitis C Protocols", *Methods in Molecular Medicine*, The Humana Press Inc., Totowa U.S.A., 1998, p. 451-61.
- 171) Martinetti M, Hammer J, Asti M, Badulli C, D'Aronzo AM, Cuccia M, Moretta A, Maccario R, Ferrarotti I, **Mondelli MU**, Silini E, Cividini A, Salvaneschi L. *In vitro* T-cell immune reactivity against promiscuous frames on hepatitis C virus core protein predicted by computational analysis. In Hansen JA and Dupont BO (Editors). *HLA 2002: immunobiology of the human MHC*. IHWG press, Seattle, USA.
- 172) **Mondelli MU**, Barnaba V. Regulatory cell subsets involved in immunotolerance and immunosuppression. In: Moreno-Otero R, Albillos A, Bañares R, Cuervas-Mons V, Medina J (Eds.) *Immunology and the Liver: Immunotherapy*. Accion Medica, Madrid, Spain, 2004, pp. 3-8.
- 173) **Mondelli MU**, Cerino A, Varchetta S. Linking viral infections to autoimmunity: B-cell activation in chronic hepatitis C. *Accion Medica*, Madrid, Spain, 2006, pp. 79-86.
- 174) **Mondelli MU**, Oliviero B, Paudice E, Varchetta S, Zaramella M, Michelone G, Gulminetti R, Cerino A. Protective and damaging immune responses to hepatitis C virus. In: Buti M, Esteban R (Eds.) *Viral Hepatitis*, Barcelona 2008.
- 175) Ferrari C, **Mondelli MU**. Immune mechanisms of viral clearance and disease pathogenesis during viral hepatitis. In Arias I. (Ed.), *Liver Biology and Pathobiology*, 2010.
- 176) **Mondelli MU**, Varchetta S, Negro F. Hepatitis C virus. In: Gershwin ME, Vierling JM, Manns MP, eds. *Liver Immunology*, New York, NY: Springer, 2014, 207-30.